CA3037008A1

CA3037008A1 - Methods for treating cancer with bavituximab based on levels of .beta.2-glycoprotein 1, and assays therefor

Methods for treating cancer with bavituximab based on levels of .beta.2-glycoprotein 1, and assays therefor Download PDF

Info

Publication number: CA3037008A1
Authority: CA; Canada
Prior art keywords: bavituximab; cancer; beta; antibody; functional
Prior art date: 2016-09-27
Legal status : Abandoned

Application number

CA3037008A

Other languages

English (en)

French (fr)

Inventor

Min Tang

Joseph S. Shan

Steven W. King

Connie Chang

Michael A. Brown

Current Assignee

Feng Biosciences Inc

Original Assignee

Oncologie Inc

Priority date

2016-09-27

Filing date

2017-09-26

Publication date

2018-04-05

2017-09-26 Application filed by Oncologie Inc filed Critical Oncologie Inc

2018-04-05 Publication of CA3037008A1 publication Critical patent/CA3037008A1/en

Status Abandoned legal-status Critical Current

Links

229950007843 bavituximab Drugs 0.000 title claims abstract description 538
206010028980 Neoplasm Diseases 0.000 title claims abstract description 207
238000000034 method Methods 0.000 title claims abstract description 100
201000011510 cancer Diseases 0.000 title claims abstract description 78
238000003556 assay Methods 0.000 title claims description 103
210000004369 blood Anatomy 0.000 claims abstract description 78
239000008280 blood Substances 0.000 claims abstract description 78
238000002203 pretreatment Methods 0.000 claims abstract description 66
ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 claims description 455
TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 claims description 446
238000009739 binding Methods 0.000 claims description 247
230000027455 binding Effects 0.000 claims description 242
241000282414 Homo sapiens Species 0.000 claims description 121
ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims description 100
229960003668 docetaxel Drugs 0.000 claims description 100
239000000523 sample Substances 0.000 claims description 94
210000002966 serum Anatomy 0.000 claims description 89
239000002246 antineoplastic agent Substances 0.000 claims description 78
238000002965 ELISA Methods 0.000 claims description 72
239000003795 chemical substances by application Substances 0.000 claims description 64
208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 47
208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 47
230000000903 blocking effect Effects 0.000 claims description 39
102100040678 Programmed cell death protein 1 Human genes 0.000 claims description 37
101710089372 Programmed cell death protein 1 Proteins 0.000 claims description 37
229940045513 CTLA4 antagonist Drugs 0.000 claims description 28
239000012472 biological sample Substances 0.000 claims description 26
108010021064 CTLA-4 Antigen Proteins 0.000 claims description 25
102000008203 CTLA-4 Antigen Human genes 0.000 claims description 25
102000037982 Immune checkpoint proteins Human genes 0.000 claims description 24
108091008036 Immune checkpoint proteins Proteins 0.000 claims description 24
229960005277 gemcitabine Drugs 0.000 claims description 22
SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims description 22
206010073071 hepatocellular carcinoma Diseases 0.000 claims description 18
208000026310 Breast neoplasm Diseases 0.000 claims description 17
229930012538 Paclitaxel Natural products 0.000 claims description 17
229960001592 paclitaxel Drugs 0.000 claims description 17
RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 17
206010061902 Pancreatic neoplasm Diseases 0.000 claims description 16
201000002528 pancreatic cancer Diseases 0.000 claims description 15
206010006187 Breast cancer Diseases 0.000 claims description 14
229960004562 carboplatin Drugs 0.000 claims description 14
MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 claims description 13
239000005511 L01XE05 - Sorafenib Substances 0.000 claims description 13
229940127089 cytotoxic agent Drugs 0.000 claims description 13
208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 13
201000001441 melanoma Diseases 0.000 claims description 13
208000008443 pancreatic carcinoma Diseases 0.000 claims description 13
229960003787 sorafenib Drugs 0.000 claims description 13
108010074708 B7-H1 Antigen Proteins 0.000 claims description 12
208000006265 Renal cell carcinoma Diseases 0.000 claims description 11
190000008236 carboplatin Chemical compound 0.000 claims description 11
229950009791 durvalumab Drugs 0.000 claims description 11
231100000844 hepatocellular carcinoma Toxicity 0.000 claims description 10
206010005003 Bladder cancer Diseases 0.000 claims description 9
208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 9
239000011248 coating agent Substances 0.000 claims description 9
238000000576 coating method Methods 0.000 claims description 9
229960003301 nivolumab Drugs 0.000 claims description 9
201000005112 urinary bladder cancer Diseases 0.000 claims description 9
229960003852 atezolizumab Drugs 0.000 claims description 8
208000005017 glioblastoma Diseases 0.000 claims description 8
206010058467 Lung neoplasm malignant Diseases 0.000 claims description 7
206010033128 Ovarian cancer Diseases 0.000 claims description 7
206010061535 Ovarian neoplasm Diseases 0.000 claims description 7
208000014829 head and neck neoplasm Diseases 0.000 claims description 7
201000005202 lung cancer Diseases 0.000 claims description 7
208000020816 lung neoplasm Diseases 0.000 claims description 7
229950007217 tremelimumab Drugs 0.000 claims description 7
206010060862 Prostate cancer Diseases 0.000 claims description 6
208000000236 Prostatic Neoplasms Diseases 0.000 claims description 6
201000010536 head and neck cancer Diseases 0.000 claims description 6
229960002621 pembrolizumab Drugs 0.000 claims description 6
208000001333 Colorectal Neoplasms Diseases 0.000 claims description 5
206010018338 Glioma Diseases 0.000 claims description 5
208000005718 Stomach Neoplasms Diseases 0.000 claims description 5
206010017758 gastric cancer Diseases 0.000 claims description 5
201000011549 stomach cancer Diseases 0.000 claims description 5
206010009944 Colon cancer Diseases 0.000 claims description 4
208000000461 Esophageal Neoplasms Diseases 0.000 claims description 4
206010030155 Oesophageal carcinoma Diseases 0.000 claims description 4
201000004101 esophageal cancer Diseases 0.000 claims description 4
208000029824 high grade glioma Diseases 0.000 claims description 3
201000011614 malignant glioma Diseases 0.000 claims description 3
102000008096 B7-H1 Antigen Human genes 0.000 claims 1
238000011282 treatment Methods 0.000 abstract description 172
238000002648 combination therapy Methods 0.000 abstract description 33
102100030802 Beta-2-glycoprotein 1 Human genes 0.000 abstract description 2
210000004027 cell Anatomy 0.000 description 204
239000000090 biomarker Substances 0.000 description 88
239000012071 phase Substances 0.000 description 79
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 69
239000003814 drug Substances 0.000 description 68
201000010099 disease Diseases 0.000 description 66
241000699666 Mus <mouse, genus> Species 0.000 description 56
230000004083 survival effect Effects 0.000 description 51
230000004044 response Effects 0.000 description 45
108090000623 proteins and genes Proteins 0.000 description 43
238000002560 therapeutic procedure Methods 0.000 description 38
102000004169 proteins and genes Human genes 0.000 description 36
238000012360 testing method Methods 0.000 description 36
241000699670 Mus sp. Species 0.000 description 35
238000010790 dilution Methods 0.000 description 35
239000012895 dilution Substances 0.000 description 35
241001465754 Metazoa Species 0.000 description 34
229940124597 therapeutic agent Drugs 0.000 description 34
230000001225 therapeutic effect Effects 0.000 description 34
230000000259 anti-tumor effect Effects 0.000 description 33
239000007787 solid Substances 0.000 description 32
RYCNUMLMNKHWPZ-SNVBAGLBSA-N 1-acetyl-sn-glycero-3-phosphocholine Chemical compound CC(=O)OC[C@@H](O)COP([O-])(=O)OCC[N+](C)(C)C RYCNUMLMNKHWPZ-SNVBAGLBSA-N 0.000 description 31
238000004458 analytical method Methods 0.000 description 30
230000000694 effects Effects 0.000 description 29
239000000902 placebo Substances 0.000 description 28
229940068196 placebo Drugs 0.000 description 28
108091003079 Bovine Serum Albumin Proteins 0.000 description 27
208000036142 Viral infection Diseases 0.000 description 27
241000700605 Viruses Species 0.000 description 27
238000001514 detection method Methods 0.000 description 27
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 27
239000002953 phosphate buffered saline Substances 0.000 description 27
230000009385 viral infection Effects 0.000 description 27
210000002381 plasma Anatomy 0.000 description 26
238000001727 in vivo Methods 0.000 description 25
102000004506 Blood Proteins Human genes 0.000 description 22
108010017384 Blood Proteins Proteins 0.000 description 22
210000004408 hybridoma Anatomy 0.000 description 22
208000015181 infectious disease Diseases 0.000 description 22
239000000203 mixture Substances 0.000 description 22
230000003612 virological effect Effects 0.000 description 22
230000003442 weekly effect Effects 0.000 description 22
210000004204 blood vessel Anatomy 0.000 description 21
239000000872 buffer Substances 0.000 description 21
230000001419 dependent effect Effects 0.000 description 21
210000001808 exosome Anatomy 0.000 description 21
239000012091 fetal bovine serum Substances 0.000 description 21
210000004881 tumor cell Anatomy 0.000 description 21
241000711549 Hepacivirus C Species 0.000 description 20
-1 anionic phospholipids Chemical class 0.000 description 20
230000001965 increasing effect Effects 0.000 description 20
239000012528 membrane Substances 0.000 description 20
229940079593 drug Drugs 0.000 description 19
230000001506 immunosuppresive effect Effects 0.000 description 19
238000009169 immunotherapy Methods 0.000 description 19
238000000338 in vitro Methods 0.000 description 18
239000003550 marker Substances 0.000 description 18
230000007246 mechanism Effects 0.000 description 18
241000283690 Bos taurus Species 0.000 description 17
241001529936 Murinae Species 0.000 description 17
230000008901 benefit Effects 0.000 description 17
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 17
239000000243 solution Substances 0.000 description 17
230000000840 anti-viral effect Effects 0.000 description 16
238000009826 distribution Methods 0.000 description 16
239000000427 antigen Substances 0.000 description 15
108091007433 antigens Proteins 0.000 description 15
102000036639 antigens Human genes 0.000 description 15
230000014509 gene expression Effects 0.000 description 15
238000002512 chemotherapy Methods 0.000 description 14
238000011161 development Methods 0.000 description 14
230000018109 developmental process Effects 0.000 description 14
150000003904 phospholipids Chemical class 0.000 description 14
230000002035 prolonged effect Effects 0.000 description 14
239000000758 substrate Substances 0.000 description 14
239000006144 Dulbecco’s modiﬁed Eagle's medium Substances 0.000 description 13
229940076838 Immune checkpoint inhibitor Drugs 0.000 description 13
102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 description 13
230000001093 anti-cancer Effects 0.000 description 13
239000012274 immune-checkpoint protein inhibitor Substances 0.000 description 13
230000001404 mediated effect Effects 0.000 description 13
230000001717 pathogenic effect Effects 0.000 description 13
102000005962 receptors Human genes 0.000 description 13
239000006228 supernatant Substances 0.000 description 13
239000013598 vector Substances 0.000 description 13
208000003343 Antiphospholipid Syndrome Diseases 0.000 description 12
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
238000002360 preparation method Methods 0.000 description 12
108010001336 Horseradish Peroxidase Proteins 0.000 description 11
108010058846 Ovalbumin Proteins 0.000 description 11
230000009286 beneficial effect Effects 0.000 description 11
210000000170 cell membrane Anatomy 0.000 description 11
210000002889 endothelial cell Anatomy 0.000 description 11
230000006870 function Effects 0.000 description 11
230000001976 improved effect Effects 0.000 description 11
208000014018 liver neoplasm Diseases 0.000 description 11
239000000463 material Substances 0.000 description 11
229940092253 ovalbumin Drugs 0.000 description 11
WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 11
239000000047 product Substances 0.000 description 11
238000000159 protein binding assay Methods 0.000 description 11
238000013207 serial dilution Methods 0.000 description 11
FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 10
230000001594 aberrant effect Effects 0.000 description 10
230000009471 action Effects 0.000 description 10
230000003993 interaction Effects 0.000 description 10
230000009467 reduction Effects 0.000 description 10
241000282412 Homo Species 0.000 description 9
241000725303 Human immunodeficiency virus Species 0.000 description 9
102000003992 Peroxidases Human genes 0.000 description 9
210000001744 T-lymphocyte Anatomy 0.000 description 9
230000007423 decrease Effects 0.000 description 9
ZGSPNIOCEDOHGS-UHFFFAOYSA-L disodium [3-[2,3-di(octadeca-9,12-dienoyloxy)propoxy-oxidophosphoryl]oxy-2-hydroxypropyl] 2,3-di(octadeca-9,12-dienoyloxy)propyl phosphate Chemical compound [Na+].[Na+].CCCCCC=CCC=CCCCCCCCC(=O)OCC(OC(=O)CCCCCCCC=CCC=CCCCCC)COP([O-])(=O)OCC(O)COP([O-])(=O)OCC(OC(=O)CCCCCCCC=CCC=CCCCCC)COC(=O)CCCCCCCC=CCC=CCCCCC ZGSPNIOCEDOHGS-UHFFFAOYSA-L 0.000 description 9
238000003384 imaging method Methods 0.000 description 9
150000007523 nucleic acids Chemical class 0.000 description 9
108040007629 peroxidase activity proteins Proteins 0.000 description 9
239000004017 serum-free culture medium Substances 0.000 description 9
210000005166 vasculature Anatomy 0.000 description 9
MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 8
102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 description 8
108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 description 8
241000700159 Rattus Species 0.000 description 8
230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 8
239000012530 fluid Substances 0.000 description 8
238000011534 incubation Methods 0.000 description 8
201000008443 lung non-squamous non-small cell carcinoma Diseases 0.000 description 8
239000002245 particle Substances 0.000 description 8
229940012957 plasmin Drugs 0.000 description 8
102000005912 ran GTP Binding Protein Human genes 0.000 description 8
108020003175 receptors Proteins 0.000 description 8
206010055113 Breast cancer metastatic Diseases 0.000 description 7
101100112922 Candida albicans CDR3 gene Proteins 0.000 description 7
102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 description 7
108010047041 Complementarity Determining Regions Proteins 0.000 description 7
102000004127 Cytokines Human genes 0.000 description 7
108090000695 Cytokines Proteins 0.000 description 7
108010088842 Fibrinolysin Proteins 0.000 description 7
230000003213 activating effect Effects 0.000 description 7
210000000577 adipose tissue Anatomy 0.000 description 7
239000003443 antiviral agent Substances 0.000 description 7
230000001684 chronic effect Effects 0.000 description 7
238000003776 cleavage reaction Methods 0.000 description 7
210000004443 dendritic cell Anatomy 0.000 description 7
239000003085 diluting agent Substances 0.000 description 7
MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 7
210000002865 immune cell Anatomy 0.000 description 7
230000028993 immune response Effects 0.000 description 7
230000004576 lipid-binding Effects 0.000 description 7
210000002540 macrophage Anatomy 0.000 description 7
108020004707 nucleic acids Proteins 0.000 description 7
102000039446 nucleic acids Human genes 0.000 description 7
244000052769 pathogen Species 0.000 description 7
239000013641 positive control Substances 0.000 description 7
230000007017 scission Effects 0.000 description 7
238000001356 surgical procedure Methods 0.000 description 7
230000001988 toxicity Effects 0.000 description 7
231100000419 toxicity Toxicity 0.000 description 7
230000004614 tumor growth Effects 0.000 description 7
238000005406 washing Methods 0.000 description 7
238000001262 western blot Methods 0.000 description 7
PORPENFLTBBHSG-MGBGTMOVSA-N 1,2-dihexadecanoyl-sn-glycerol-3-phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(O)=O)OC(=O)CCCCCCCCCCCCCCC PORPENFLTBBHSG-MGBGTMOVSA-N 0.000 description 6
206010062016 Immunosuppression Diseases 0.000 description 6
102000014150 Interferons Human genes 0.000 description 6
108010050904 Interferons Proteins 0.000 description 6
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
239000007983 Tris buffer Substances 0.000 description 6
239000004037 angiogenesis inhibitor Substances 0.000 description 6
230000005975 antitumor immune response Effects 0.000 description 6
230000006907 apoptotic process Effects 0.000 description 6
238000013459 approach Methods 0.000 description 6
230000015572 biosynthetic process Effects 0.000 description 6
229940098773 bovine serum albumin Drugs 0.000 description 6
238000006243 chemical reaction Methods 0.000 description 6
229940044683 chemotherapy drug Drugs 0.000 description 6
239000012636 effector Substances 0.000 description 6
238000002825 functional assay Methods 0.000 description 6
210000000987 immune system Anatomy 0.000 description 6
230000003053 immunization Effects 0.000 description 6
238000002649 immunization Methods 0.000 description 6
238000003119 immunoblot Methods 0.000 description 6
230000002401 inhibitory effect Effects 0.000 description 6
229940079322 interferon Drugs 0.000 description 6
244000000056 intracellular parasite Species 0.000 description 6
210000004185 liver Anatomy 0.000 description 6
239000002609 medium Substances 0.000 description 6
230000001394 metastastic effect Effects 0.000 description 6
206010061289 metastatic neoplasm Diseases 0.000 description 6
244000309711 non-enveloped viruses Species 0.000 description 6
238000011002 quantification Methods 0.000 description 6
230000005855 radiation Effects 0.000 description 6
230000002829 reductive effect Effects 0.000 description 6
238000012216 screening Methods 0.000 description 6
241000894007 species Species 0.000 description 6
210000001519 tissue Anatomy 0.000 description 6
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 6
210000002845 virion Anatomy 0.000 description 6
CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 5
IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 5
238000011579 SCID mouse model Methods 0.000 description 5
229920002684 Sepharose Polymers 0.000 description 5
208000007536 Thrombosis Diseases 0.000 description 5
ATBOMIWRCZXYSZ-XZBBILGWSA-N [1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-hexadecanoyloxypropan-2-yl] (9e,12e)-octadeca-9,12-dienoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCC\C=C\C\C=C\CCCCC ATBOMIWRCZXYSZ-XZBBILGWSA-N 0.000 description 5
238000009825 accumulation Methods 0.000 description 5
230000002411 adverse Effects 0.000 description 5
AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 5
238000010171 animal model Methods 0.000 description 5
239000012888 bovine serum Substances 0.000 description 5
210000000481 breast Anatomy 0.000 description 5
238000002619 cancer immunotherapy Methods 0.000 description 5
235000011089 carbon dioxide Nutrition 0.000 description 5
239000003593 chromogenic compound Substances 0.000 description 5
238000003745 diagnosis Methods 0.000 description 5
208000037765 diseases and disorders Diseases 0.000 description 5
230000002708 enhancing effect Effects 0.000 description 5
239000012634 fragment Substances 0.000 description 5
230000005934 immune activation Effects 0.000 description 5
108091008915 immune receptors Proteins 0.000 description 5
229940127121 immunoconjugate Drugs 0.000 description 5
238000001802 infusion Methods 0.000 description 5
230000003834 intracellular effect Effects 0.000 description 5
150000003905 phosphatidylinositols Chemical class 0.000 description 5
230000008569 process Effects 0.000 description 5
238000000746 purification Methods 0.000 description 5
230000009257 reactivity Effects 0.000 description 5
238000011160 research Methods 0.000 description 5
229960000329 ribavirin Drugs 0.000 description 5
HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 description 5
239000007790 solid phase Substances 0.000 description 5
230000008685 targeting Effects 0.000 description 5
230000002792 vascular Effects 0.000 description 5
UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical compound CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 description 4
108090000672 Annexin A5 Proteins 0.000 description 4
102000004121 Annexin A5 Human genes 0.000 description 4
241000283707 Capra Species 0.000 description 4
241000282693 Cercopithecidae Species 0.000 description 4
238000012286 ELISA Assay Methods 0.000 description 4
241000709661 Enterovirus Species 0.000 description 4
108090000790 Enzymes Proteins 0.000 description 4
102000004190 Enzymes Human genes 0.000 description 4
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 4
206010072579 Granulomatosis with polyangiitis Diseases 0.000 description 4
208000017604 Hodgkin disease Diseases 0.000 description 4
208000008839 Kidney Neoplasms Diseases 0.000 description 4
ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 4
206010061309 Neoplasm progression Diseases 0.000 description 4
206010035226 Plasma cell myeloma Diseases 0.000 description 4
201000004613 Pseudoxanthoma elasticum Diseases 0.000 description 4
102000007056 Recombinant Fusion Proteins Human genes 0.000 description 4
108010008281 Recombinant Fusion Proteins Proteins 0.000 description 4
206010038933 Retinopathy of prematurity Diseases 0.000 description 4
206010040047 Sepsis Diseases 0.000 description 4
241000607479 Yersinia pestis Species 0.000 description 4
238000002835 absorbance Methods 0.000 description 4
230000003044 adaptive effect Effects 0.000 description 4
239000000654 additive Substances 0.000 description 4
230000000996 additive effect Effects 0.000 description 4
150000001413 amino acids Chemical group 0.000 description 4
230000033115 angiogenesis Effects 0.000 description 4
230000002491 angiogenic effect Effects 0.000 description 4
239000011230 binding agent Substances 0.000 description 4
238000004166 bioassay Methods 0.000 description 4
239000013060 biological fluid Substances 0.000 description 4
239000003153 chemical reaction reagent Substances 0.000 description 4
238000010367 cloning Methods 0.000 description 4
230000008406 drug-drug interaction Effects 0.000 description 4
229940088598 enzyme Drugs 0.000 description 4
210000003743 erythrocyte Anatomy 0.000 description 4
239000013604 expression vector Substances 0.000 description 4
206010016256 fatigue Diseases 0.000 description 4
230000002496 gastric effect Effects 0.000 description 4
239000000499 gel Substances 0.000 description 4
239000002955 immunomodulating agent Substances 0.000 description 4
230000001024 immunotherapeutic effect Effects 0.000 description 4
230000006872 improvement Effects 0.000 description 4
230000006698 induction Effects 0.000 description 4
229960005386 ipilimumab Drugs 0.000 description 4
206010023332 keratitis Diseases 0.000 description 4
210000003734 kidney Anatomy 0.000 description 4
210000004072 lung Anatomy 0.000 description 4
208000002780 macular degeneration Diseases 0.000 description 4
238000004519 manufacturing process Methods 0.000 description 4
231100000682 maximum tolerated dose Toxicity 0.000 description 4
238000005259 measurement Methods 0.000 description 4
230000004048 modification Effects 0.000 description 4
238000012986 modification Methods 0.000 description 4
230000035772 mutation Effects 0.000 description 4
210000004985 myeloid-derived suppressor cell Anatomy 0.000 description 4
230000007935 neutral effect Effects 0.000 description 4
230000003071 parasitic effect Effects 0.000 description 4
230000037361 pathway Effects 0.000 description 4
150000008104 phosphatidylethanolamines Chemical class 0.000 description 4
108091008146 restriction endonucleases Proteins 0.000 description 4
230000011664 signaling Effects 0.000 description 4
210000003491 skin Anatomy 0.000 description 4
239000011780 sodium chloride Substances 0.000 description 4
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 4
239000012089 stop solution Substances 0.000 description 4
239000013589 supplement Substances 0.000 description 4
230000002195 synergetic effect Effects 0.000 description 4
238000002626 targeted therapy Methods 0.000 description 4
230000036964 tight binding Effects 0.000 description 4
230000036962 time dependent Effects 0.000 description 4
230000001052 transient effect Effects 0.000 description 4
230000005751 tumor progression Effects 0.000 description 4
238000011144 upstream manufacturing Methods 0.000 description 4
210000003556 vascular endothelial cell Anatomy 0.000 description 4
108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 description 3
102100028187 ATP-binding cassette sub-family C member 6 Human genes 0.000 description 3
102000002260 Alkaline Phosphatase Human genes 0.000 description 3
108020004774 Alkaline Phosphatase Proteins 0.000 description 3
206010003445 Ascites Diseases 0.000 description 3
238000011725 BALB/c mouse Methods 0.000 description 3
206010004446 Benign prostatic hyperplasia Diseases 0.000 description 3
206010008190 Cerebrovascular accident Diseases 0.000 description 3
208000005590 Choroidal Neovascularization Diseases 0.000 description 3
206010060823 Choroidal neovascularisation Diseases 0.000 description 3
108091026890 Coding region Proteins 0.000 description 3
206010061818 Disease progression Diseases 0.000 description 3
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
108010000912 Egg Proteins Proteins 0.000 description 3
102000002322 Egg Proteins Human genes 0.000 description 3
241000991587 Enterovirus C Species 0.000 description 3
101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 3
206010061218 Inflammation Diseases 0.000 description 3
102000003814 Interleukin-10 Human genes 0.000 description 3
108090000174 Interleukin-10 Proteins 0.000 description 3
108010065805 Interleukin-12 Proteins 0.000 description 3
102000013462 Interleukin-12 Human genes 0.000 description 3
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
102000017578 LAG3 Human genes 0.000 description 3
101150030213 Lag3 gene Proteins 0.000 description 3
208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 description 3
206010029113 Neovascularisation Diseases 0.000 description 3
239000004793 Polystyrene Substances 0.000 description 3
208000004403 Prostatic Hyperplasia Diseases 0.000 description 3
108010076504 Protein Sorting Signals Proteins 0.000 description 3
102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 3
206010038389 Renal cancer Diseases 0.000 description 3
206010041067 Small cell lung cancer Diseases 0.000 description 3
208000006011 Stroke Diseases 0.000 description 3
108090000631 Trypsin Proteins 0.000 description 3
102000004142 Trypsin Human genes 0.000 description 3
108060008682 Tumor Necrosis Factor Proteins 0.000 description 3
206010054094 Tumour necrosis Diseases 0.000 description 3
208000037844 advanced solid tumor Diseases 0.000 description 3
206010064930 age-related macular degeneration Diseases 0.000 description 3
238000002399 angioplasty Methods 0.000 description 3
230000003042 antagnostic effect Effects 0.000 description 3
230000005809 anti-tumor immunity Effects 0.000 description 3
208000030220 autosomal recessive inherited pseudoxanthoma elasticum Diseases 0.000 description 3
239000011324 bead Substances 0.000 description 3
229930189065 blasticidin Natural products 0.000 description 3
210000001772 blood platelet Anatomy 0.000 description 3
210000004556 brain Anatomy 0.000 description 3
230000030833 cell death Effects 0.000 description 3
210000001175 cerebrospinal fluid Anatomy 0.000 description 3
208000026106 cerebrovascular disease Diseases 0.000 description 3
210000000991 chicken egg Anatomy 0.000 description 3
210000004978 chinese hamster ovary cell Anatomy 0.000 description 3
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
238000011284 combination treatment Methods 0.000 description 3
239000002299 complementary DNA Substances 0.000 description 3
208000029078 coronary artery disease Diseases 0.000 description 3
230000000875 corresponding effect Effects 0.000 description 3
206010012818 diffuse large B-cell lymphoma Diseases 0.000 description 3
230000005750 disease progression Effects 0.000 description 3
208000035475 disorder Diseases 0.000 description 3
235000014103 egg white Nutrition 0.000 description 3
230000003511 endothelial effect Effects 0.000 description 3
210000003038 endothelium Anatomy 0.000 description 3
238000005516 engineering process Methods 0.000 description 3
VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 3
229960005420 etoposide Drugs 0.000 description 3
208000030533 eye disease Diseases 0.000 description 3
239000003517 fume Substances 0.000 description 3
230000004927 fusion Effects 0.000 description 3
239000011521 glass Substances 0.000 description 3
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 3
239000001963 growth medium Substances 0.000 description 3
210000003128 head Anatomy 0.000 description 3
230000005745 host immune response Effects 0.000 description 3
230000000951 immunodiffusion Effects 0.000 description 3
201000001371 inclusion conjunctivitis Diseases 0.000 description 3
230000001939 inductive effect Effects 0.000 description 3
230000004054 inflammatory process Effects 0.000 description 3
230000000977 initiatory effect Effects 0.000 description 3
229940076144 interleukin-10 Drugs 0.000 description 3
229940117681 interleukin-12 Drugs 0.000 description 3
238000001990 intravenous administration Methods 0.000 description 3
201000010982 kidney cancer Diseases 0.000 description 3
150000002632 lipids Chemical class 0.000 description 3
239000007788 liquid Substances 0.000 description 3
230000003211 malignant effect Effects 0.000 description 3
239000000178 monomer Substances 0.000 description 3
229940126619 mouse monoclonal antibody Drugs 0.000 description 3
210000000822 natural killer cell Anatomy 0.000 description 3
208000004235 neutropenia Diseases 0.000 description 3
230000000414 obstructive effect Effects 0.000 description 3
230000002611 ovarian Effects 0.000 description 3
230000036961 partial effect Effects 0.000 description 3
230000007170 pathology Effects 0.000 description 3
230000010412 perfusion Effects 0.000 description 3
210000005259 peripheral blood Anatomy 0.000 description 3
239000011886 peripheral blood Substances 0.000 description 3
150000008106 phosphatidylserines Chemical class 0.000 description 3
201000006292 polyarteritis nodosa Diseases 0.000 description 3
238000004393 prognosis Methods 0.000 description 3
210000002307 prostate Anatomy 0.000 description 3
208000023558 pseudoxanthoma elasticum (inherited or acquired) Diseases 0.000 description 3
208000037803 restenosis Diseases 0.000 description 3
238000003757 reverse transcription PCR Methods 0.000 description 3
PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 3
201000000306 sarcoidosis Diseases 0.000 description 3
229920006395 saturated elastomer Polymers 0.000 description 3
230000003248 secreting effect Effects 0.000 description 3
230000028327 secretion Effects 0.000 description 3
208000000587 small cell lung carcinoma Diseases 0.000 description 3
239000002904 solvent Substances 0.000 description 3
238000003860 storage Methods 0.000 description 3
238000011285 therapeutic regimen Methods 0.000 description 3
206010044325 trachoma Diseases 0.000 description 3
239000012588 trypsin Substances 0.000 description 3
241000701161 unidentified adenovirus Species 0.000 description 3
210000002700 urine Anatomy 0.000 description 3
210000003462 vein Anatomy 0.000 description 3
230000029812 viral genome replication Effects 0.000 description 3
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
230000029663 wound healing Effects 0.000 description 3
YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 2
NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 2
YRNWIFYIFSBPAU-UHFFFAOYSA-N 4-[4-(dimethylamino)phenyl]-n,n-dimethylaniline Chemical compound C1=CC(N(C)C)=CC=C1C1=CC=C(N(C)C)C=C1 YRNWIFYIFSBPAU-UHFFFAOYSA-N 0.000 description 2
RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
208000022211 Arteriovenous Malformations Diseases 0.000 description 2
206010003571 Astrocytoma Diseases 0.000 description 2
201000001320 Atherosclerosis Diseases 0.000 description 2
241000894006 Bacteria Species 0.000 description 2
206010044583 Bartonella Infections Diseases 0.000 description 2
201000004569 Blindness Diseases 0.000 description 2
102000015081 Blood Coagulation Factors Human genes 0.000 description 2
108010039209 Blood Coagulation Factors Proteins 0.000 description 2
208000003174 Brain Neoplasms Diseases 0.000 description 2
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
241000282472 Canis lupus familiaris Species 0.000 description 2
241000700198 Cavia Species 0.000 description 2
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical group ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
206010053567 Coagulopathies Diseases 0.000 description 2
GUBGYTABKSRVRQ-WFVLMXAXSA-N DEAE-cellulose Chemical compound OC1C(O)C(O)C(CO)O[C@H]1O[C@@H]1C(CO)OC(O)C(O)C1O GUBGYTABKSRVRQ-WFVLMXAXSA-N 0.000 description 2
108010049003 Fibrinogen Proteins 0.000 description 2
102000008946 Fibrinogen Human genes 0.000 description 2
201000008808 Fibrosarcoma Diseases 0.000 description 2
241000589602 Francisella tularensis Species 0.000 description 2
201000010915 Glioblastoma multiforme Diseases 0.000 description 2
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
102000003886 Glycoproteins Human genes 0.000 description 2
108090000288 Glycoproteins Proteins 0.000 description 2
206010019233 Headaches Diseases 0.000 description 2
102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 description 2
208000031953 Hereditary hemorrhagic telangiectasia Diseases 0.000 description 2
208000021519 Hodgkin lymphoma Diseases 0.000 description 2
208000010747 Hodgkins lymphoma Diseases 0.000 description 2
101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 2
101000801234 Homo sapiens Tumor necrosis factor receptor superfamily member 18 Proteins 0.000 description 2
241000713772 Human immunodeficiency virus 1 Species 0.000 description 2
108010021625 Immunoglobulin Fragments Proteins 0.000 description 2
102000008394 Immunoglobulin Fragments Human genes 0.000 description 2
108060001084 Luciferase Proteins 0.000 description 2
206010025323 Lymphomas Diseases 0.000 description 2
241000829100 Macaca mulatta polyomavirus 1 Species 0.000 description 2
206010025412 Macular dystrophy congenital Diseases 0.000 description 2
241000124008 Mammalia Species 0.000 description 2
108010038049 Mating Factor Proteins 0.000 description 2
208000002030 Merkel cell carcinoma Diseases 0.000 description 2
206010027476 Metastases Diseases 0.000 description 2
208000034578 Multiple myelomas Diseases 0.000 description 2
206010029266 Neuroendocrine carcinoma of the skin Diseases 0.000 description 2
201000004404 Neurofibroma Diseases 0.000 description 2
108091028043 Nucleic acid sequence Proteins 0.000 description 2
241000283973 Oryctolagus cuniculus Species 0.000 description 2
KPKZJLCSROULON-QKGLWVMZSA-N Phalloidin Chemical compound N1C(=O)[C@@H]([C@@H](O)C)NC(=O)[C@H](C)NC(=O)[C@H](C[C@@](C)(O)CO)NC(=O)[C@H](C2)NC(=O)[C@H](C)NC(=O)[C@@H]3C[C@H](O)CN3C(=O)[C@@H]1CSC1=C2C2=CC=CC=C2N1 KPKZJLCSROULON-QKGLWVMZSA-N 0.000 description 2
206010035148 Plague Diseases 0.000 description 2
206010063664 Presumed ocular histoplasmosis syndrome Diseases 0.000 description 2
241000288906 Primates Species 0.000 description 2
208000002158 Proliferative Vitreoretinopathy Diseases 0.000 description 2
206010037649 Pyogenic granuloma Diseases 0.000 description 2
206010038934 Retinopathy proliferative Diseases 0.000 description 2
241001303601 Rosacea Species 0.000 description 2
240000004808 Saccharomyces cerevisiae Species 0.000 description 2
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
206010042033 Stevens-Johnson syndrome Diseases 0.000 description 2
231100000168 Stevens-Johnson syndrome Toxicity 0.000 description 2
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
230000006044 T cell activation Effects 0.000 description 2
102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 2
NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 2
108090000373 Tissue Plasminogen Activator Proteins 0.000 description 2
102000003978 Tissue Plasminogen Activator Human genes 0.000 description 2
208000034784 Tularaemia Diseases 0.000 description 2
102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
102100033728 Tumor necrosis factor receptor superfamily member 18 Human genes 0.000 description 2
208000025865 Ulcer Diseases 0.000 description 2
108010046334 Urease Proteins 0.000 description 2
206010046851 Uveitis Diseases 0.000 description 2
206010047249 Venous thrombosis Diseases 0.000 description 2
208000014070 Vestibular schwannoma Diseases 0.000 description 2
206010052428 Wound Diseases 0.000 description 2
208000027418 Wounds and injury Diseases 0.000 description 2
208000004064 acoustic neuroma Diseases 0.000 description 2
230000001270 agonistic effect Effects 0.000 description 2
208000007502 anemia Diseases 0.000 description 2
208000022531 anorexia Diseases 0.000 description 2
230000001772 anti-angiogenic effect Effects 0.000 description 2
230000005744 arteriovenous malformation Effects 0.000 description 2
238000002820 assay format Methods 0.000 description 2
244000052616 bacterial pathogen Species 0.000 description 2
206010004145 bartonellosis Diseases 0.000 description 2
230000005540 biological transmission Effects 0.000 description 2
238000001574 biopsy Methods 0.000 description 2
210000000625 blastula Anatomy 0.000 description 2
208000002352 blister Diseases 0.000 description 2
239000003114 blood coagulation factor Substances 0.000 description 2
210000001185 bone marrow Anatomy 0.000 description 2
239000011575 calcium Substances 0.000 description 2
229910052791 calcium Inorganic materials 0.000 description 2
238000004364 calculation method Methods 0.000 description 2
230000020411 cell activation Effects 0.000 description 2
230000006037 cell lysis Effects 0.000 description 2
238000005119 centrifugation Methods 0.000 description 2
238000012512 characterization method Methods 0.000 description 2
230000000973 chemotherapeutic effect Effects 0.000 description 2
208000037976 chronic inflammation Diseases 0.000 description 2
230000004087 circulation Effects 0.000 description 2
210000003690 classically activated macrophage Anatomy 0.000 description 2
OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 description 2
230000000052 comparative effect Effects 0.000 description 2
230000000295 complement effect Effects 0.000 description 2
150000001875 compounds Chemical class 0.000 description 2
238000002508 contact lithography Methods 0.000 description 2
210000004087 cornea Anatomy 0.000 description 2
238000012864 cross contamination Methods 0.000 description 2
208000017763 cutaneous neuroendocrine carcinoma Diseases 0.000 description 2
230000009089 cytolysis Effects 0.000 description 2
230000000120 cytopathologic effect Effects 0.000 description 2
230000001086 cytosolic effect Effects 0.000 description 2
230000006378 damage Effects 0.000 description 2
230000034994 death Effects 0.000 description 2
231100000517 death Toxicity 0.000 description 2
206010061428 decreased appetite Diseases 0.000 description 2
238000013461 design Methods 0.000 description 2
230000001627 detrimental effect Effects 0.000 description 2
239000008121 dextrose Substances 0.000 description 2
206010012601 diabetes mellitus Diseases 0.000 description 2
239000004205 dimethyl polysiloxane Substances 0.000 description 2
230000009977 dual effect Effects 0.000 description 2
230000029117 egress of virus within host cell Effects 0.000 description 2
239000003623 enhancer Substances 0.000 description 2
208000001780 epistaxis Diseases 0.000 description 2
210000002919 epithelial cell Anatomy 0.000 description 2
238000011156 evaluation Methods 0.000 description 2
230000002349 favourable effect Effects 0.000 description 2
210000003608 fece Anatomy 0.000 description 2
229940012952 fibrinogen Drugs 0.000 description 2
238000000684 flow cytometry Methods 0.000 description 2
GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 2
235000013305 food Nutrition 0.000 description 2
210000000245 forearm Anatomy 0.000 description 2
238000009472 formulation Methods 0.000 description 2
229940118764 francisella tularensis Drugs 0.000 description 2
230000005714 functional activity Effects 0.000 description 2
230000013595 glycosylation Effects 0.000 description 2
238000006206 glycosylation reaction Methods 0.000 description 2
231100000869 headache Toxicity 0.000 description 2
201000011066 hemangioma Diseases 0.000 description 2
239000012642 immune effector Substances 0.000 description 2
230000008629 immune suppression Effects 0.000 description 2
238000003364 immunohistochemistry Methods 0.000 description 2
229940121354 immunomodulator Drugs 0.000 description 2
238000002513 implantation Methods 0.000 description 2
230000008595 infiltration Effects 0.000 description 2
238000001764 infiltration Methods 0.000 description 2
230000005764 inhibitory process Effects 0.000 description 2
238000002347 injection Methods 0.000 description 2
239000007924 injection Substances 0.000 description 2
208000014674 injury Diseases 0.000 description 2
230000009545 invasion Effects 0.000 description 2
238000001155 isoelectric focusing Methods 0.000 description 2
238000011813 knockout mouse model Methods 0.000 description 2
238000002372 labelling Methods 0.000 description 2
208000032839 leukemia Diseases 0.000 description 2
230000000670 limiting effect Effects 0.000 description 2
201000007270 liver cancer Diseases 0.000 description 2
230000033001 locomotion Effects 0.000 description 2
230000007774 longterm Effects 0.000 description 2
238000009115 maintenance therapy Methods 0.000 description 2
230000036210 malignancy Effects 0.000 description 2
238000004949 mass spectrometry Methods 0.000 description 2
230000008774 maternal effect Effects 0.000 description 2
SKEFKEOTNIPLCQ-LWIQTABASA-N mating hormone Chemical group C([C@@H](C(=O)NC(CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCS(C)=O)C(=O)NC(CC=1C=CC(O)=CC=1)C(O)=O)NC(=O)[C@@H](N)CC=1C2=CC=CC=C2NC=1)C1=CN=CN1 SKEFKEOTNIPLCQ-LWIQTABASA-N 0.000 description 2
230000035800 maturation Effects 0.000 description 2
238000002493 microarray Methods 0.000 description 2
239000003068 molecular probe Substances 0.000 description 2
210000001616 monocyte Anatomy 0.000 description 2
201000000050 myeloid neoplasm Diseases 0.000 description 2
208000010125 myocardial infarction Diseases 0.000 description 2
230000001338 necrotic effect Effects 0.000 description 2
239000013642 negative control Substances 0.000 description 2
208000021971 neovascular inflammatory vitreoretinopathy Diseases 0.000 description 2
238000011275 oncology therapy Methods 0.000 description 2
230000003287 optical effect Effects 0.000 description 2
230000016087 ovulation Effects 0.000 description 2
230000001575 pathological effect Effects 0.000 description 2
230000001991 pathophysiological effect Effects 0.000 description 2
VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 2
230000004962 physiological condition Effects 0.000 description 2
230000035790 physiological processes and functions Effects 0.000 description 2
239000013612 plasmid Substances 0.000 description 2
239000004033 plastic Substances 0.000 description 2
229920003023 plastic Polymers 0.000 description 2
229920000435 poly(dimethylsiloxane) Polymers 0.000 description 2
229920002223 polystyrene Polymers 0.000 description 2
239000000843 powder Substances 0.000 description 2
210000004909 pre-ejaculatory fluid Anatomy 0.000 description 2
102000004196 processed proteins & peptides Human genes 0.000 description 2
108090000765 processed proteins & peptides Proteins 0.000 description 2
230000000770 proinflammatory effect Effects 0.000 description 2
230000002062 proliferating effect Effects 0.000 description 2
230000035755 proliferation Effects 0.000 description 2
230000006785 proliferative vitreoretinopathy Effects 0.000 description 2
238000001243 protein synthesis Methods 0.000 description 2
230000003331 prothrombotic effect Effects 0.000 description 2
230000003439 radiotherapeutic effect Effects 0.000 description 2
238000001959 radiotherapy Methods 0.000 description 2
230000000717 retained effect Effects 0.000 description 2
238000012552 review Methods 0.000 description 2
229960004641 rituximab Drugs 0.000 description 2
201000004700 rosacea Diseases 0.000 description 2
238000005464 sample preparation method Methods 0.000 description 2
238000009738 saturating Methods 0.000 description 2
210000000582 semen Anatomy 0.000 description 2
230000035945 sensitivity Effects 0.000 description 2
238000012163 sequencing technique Methods 0.000 description 2
208000007056 sickle cell anemia Diseases 0.000 description 2
230000019491 signal transduction Effects 0.000 description 2
238000002764 solid phase assay Methods 0.000 description 2
238000007619 statistical method Methods 0.000 description 2
230000004936 stimulating effect Effects 0.000 description 2
239000011550 stock solution Substances 0.000 description 2
238000007920 subcutaneous administration Methods 0.000 description 2
238000010254 subcutaneous injection Methods 0.000 description 2
239000007929 subcutaneous injection Substances 0.000 description 2
235000011149 sulphuric acid Nutrition 0.000 description 2
230000008093 supporting effect Effects 0.000 description 2
238000010998 test method Methods 0.000 description 2
230000002381 testicular Effects 0.000 description 2
MPLHNVLQVRSVEE-UHFFFAOYSA-N texas red Chemical compound [O-]S(=O)(=O)C1=CC(S(Cl)(=O)=O)=CC=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 MPLHNVLQVRSVEE-UHFFFAOYSA-N 0.000 description 2
238000010257 thawing Methods 0.000 description 2
210000000115 thoracic cavity Anatomy 0.000 description 2
229960000187 tissue plasminogen activator Drugs 0.000 description 2
238000012546 transfer Methods 0.000 description 2
230000014616 translation Effects 0.000 description 2
230000005945 translocation Effects 0.000 description 2
230000008733 trauma Effects 0.000 description 2
238000011269 treatment regimen Methods 0.000 description 2
201000008827 tuberculosis Diseases 0.000 description 2
210000004981 tumor-associated macrophage Anatomy 0.000 description 2
231100000397 ulcer Toxicity 0.000 description 2
201000007790 vitelliform macular dystrophy Diseases 0.000 description 2
239000011534 wash buffer Substances 0.000 description 2
RFBVBRVVOPAAFS-UHFFFAOYSA-N 2,2-bis(hydroxymethyl)-1-azabicyclo[2.2.2]octan-3-one Chemical compound C1CC2CCN1C(CO)(CO)C2=O RFBVBRVVOPAAFS-UHFFFAOYSA-N 0.000 description 1
NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
KUWPCJHYPSUOFW-YBXAARCKSA-N 2-nitrophenyl beta-D-galactoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CC=CC=C1[N+]([O-])=O KUWPCJHYPSUOFW-YBXAARCKSA-N 0.000 description 1
XZKIHKMTEMTJQX-UHFFFAOYSA-N 4-Nitrophenyl Phosphate Chemical compound OP(O)(=O)OC1=CC=C([N+]([O-])=O)C=C1 XZKIHKMTEMTJQX-UHFFFAOYSA-N 0.000 description 1
GZAJOEGTZDUSKS-UHFFFAOYSA-N 5-aminofluorescein Chemical compound C12=CC=C(O)C=C2OC2=CC(O)=CC=C2C21OC(=O)C1=CC(N)=CC=C21 GZAJOEGTZDUSKS-UHFFFAOYSA-N 0.000 description 1
102100033793 ALK tyrosine kinase receptor Human genes 0.000 description 1
208000024827 Alzheimer disease Diseases 0.000 description 1
201000000736 Amenorrhea Diseases 0.000 description 1
206010001928 Amenorrhoea Diseases 0.000 description 1
206010002091 Anaesthesia Diseases 0.000 description 1
208000003120 Angiofibroma Diseases 0.000 description 1
108050008874 Annexin Proteins 0.000 description 1
102000000412 Annexin Human genes 0.000 description 1
244000303258 Annona diversifolia Species 0.000 description 1
235000002198 Annona diversifolia Nutrition 0.000 description 1
241000712892 Arenaviridae Species 0.000 description 1
206010003178 Arterial thrombosis Diseases 0.000 description 1
206010003211 Arteriosclerosis coronary artery Diseases 0.000 description 1
206010003226 Arteriovenous fistula Diseases 0.000 description 1
208000037260 Atherosclerotic Plaque Diseases 0.000 description 1
206010003645 Atopy Diseases 0.000 description 1
206010003658 Atrial Fibrillation Diseases 0.000 description 1
208000023275 Autoimmune disease Diseases 0.000 description 1
229940125565 BMS-986016 Drugs 0.000 description 1
241000223838 Babesia bovis Species 0.000 description 1
208000008035 Back Pain Diseases 0.000 description 1
208000035143 Bacterial infection Diseases 0.000 description 1
208000009137 Behcet syndrome Diseases 0.000 description 1
241000157302 Bison bison athabascae Species 0.000 description 1
206010006002 Bone pain Diseases 0.000 description 1
241000589562 Brucella Species 0.000 description 1
206010006500 Brucellosis Diseases 0.000 description 1
201000002829 CREST Syndrome Diseases 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
201000009030 Carcinoma Diseases 0.000 description 1
241000700199 Cavia porcellus Species 0.000 description 1
206010008132 Cerebral thrombosis Diseases 0.000 description 1
208000009043 Chemical Burns Diseases 0.000 description 1
241000606161 Chlamydia Species 0.000 description 1
208000007190 Chlamydia Infections Diseases 0.000 description 1
241000606153 Chlamydia trachomatis Species 0.000 description 1
208000002691 Choroiditis Diseases 0.000 description 1
208000006154 Chronic hepatitis C Diseases 0.000 description 1
208000032544 Cicatrix Diseases 0.000 description 1
108020004705 Codon Proteins 0.000 description 1
206010009900 Colitis ulcerative Diseases 0.000 description 1
208000035473 Communicable disease Diseases 0.000 description 1
206010010741 Conjunctivitis Diseases 0.000 description 1
206010010774 Constipation Diseases 0.000 description 1
206010011017 Corneal graft rejection Diseases 0.000 description 1
206010055665 Corneal neovascularisation Diseases 0.000 description 1
206010011091 Coronary artery thrombosis Diseases 0.000 description 1
241000709675 Coxsackievirus B3 Species 0.000 description 1
241000699800 Cricetinae Species 0.000 description 1
241000699802 Cricetulus griseus Species 0.000 description 1
208000011231 Crohn disease Diseases 0.000 description 1
108020004414 DNA Proteins 0.000 description 1
230000005778 DNA damage Effects 0.000 description 1
231100000277 DNA damage Toxicity 0.000 description 1
206010051055 Deep vein thrombosis Diseases 0.000 description 1
201000004624 Dermatitis Diseases 0.000 description 1
206010012689 Diabetic retinopathy Diseases 0.000 description 1
206010012735 Diarrhoea Diseases 0.000 description 1
206010013710 Drug interaction Diseases 0.000 description 1
206010013774 Dry eye Diseases 0.000 description 1
208000019878 Eales disease Diseases 0.000 description 1
201000009273 Endometriosis Diseases 0.000 description 1
241000283086 Equidae Species 0.000 description 1
208000001860 Eye Infections Diseases 0.000 description 1
108010080865 Factor XII Proteins 0.000 description 1
102000000429 Factor XII Human genes 0.000 description 1
208000002633 Febrile Neutropenia Diseases 0.000 description 1
241000282326 Felis catus Species 0.000 description 1
241000711950 Filoviridae Species 0.000 description 1
241000710781 Flaviviridae Species 0.000 description 1
206010016952 Food poisoning Diseases 0.000 description 1
208000019331 Foodborne disease Diseases 0.000 description 1
238000011770 Fox Chase SCID mouse Methods 0.000 description 1
241000233866 Fungi Species 0.000 description 1
208000010412 Glaucoma Diseases 0.000 description 1
208000032612 Glial tumor Diseases 0.000 description 1
239000004471 Glycine Substances 0.000 description 1
108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
206010018691 Granuloma Diseases 0.000 description 1
208000003807 Graves Disease Diseases 0.000 description 1
208000015023 Graves' disease Diseases 0.000 description 1
239000007995 HEPES buffer Substances 0.000 description 1
208000031886 HIV Infections Diseases 0.000 description 1
208000010496 Heart Arrest Diseases 0.000 description 1
241000590002 Helicobacter pylori Species 0.000 description 1
208000002250 Hematologic Neoplasms Diseases 0.000 description 1
208000032843 Hemorrhage Diseases 0.000 description 1
208000024659 Hemostatic disease Diseases 0.000 description 1
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
101710083479 Hepatitis A virus cellular receptor 2 homolog Proteins 0.000 description 1
208000005176 Hepatitis C Diseases 0.000 description 1
206010019973 Herpes virus infection Diseases 0.000 description 1
241000700586 Herpesviridae Species 0.000 description 1
101000942697 Homo sapiens Clusterin Proteins 0.000 description 1
101001068133 Homo sapiens Hepatitis A virus cellular receptor 2 Proteins 0.000 description 1
206010020772 Hypertension Diseases 0.000 description 1
206010051151 Hyperviscosity syndrome Diseases 0.000 description 1
206010021143 Hypoxia Diseases 0.000 description 1
108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
206010051792 Infusion related reaction Diseases 0.000 description 1
102000008070 Interferon-gamma Human genes 0.000 description 1
108010074328 Interferon-gamma Proteins 0.000 description 1
108010002350 Interleukin-2 Proteins 0.000 description 1
108090001005 Interleukin-6 Proteins 0.000 description 1
201000001429 Intracranial Thrombosis Diseases 0.000 description 1
206010022941 Iridocyclitis Diseases 0.000 description 1
208000012659 Joint disease Diseases 0.000 description 1
208000002260 Keloid Diseases 0.000 description 1
YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
108010077861 Kininogens Proteins 0.000 description 1
102000010631 Kininogens Human genes 0.000 description 1
241000235058 Komagataella pastoris Species 0.000 description 1
229930182816 L-glutamine Natural products 0.000 description 1
239000005551 L01XE03 - Erlotinib Substances 0.000 description 1
239000002147 L01XE04 - Sunitinib Substances 0.000 description 1
241000589242 Legionella pneumophila Species 0.000 description 1
208000007764 Legionnaires' Disease Diseases 0.000 description 1
241000222724 Leishmania amazonensis Species 0.000 description 1
208000004554 Leishmaniasis Diseases 0.000 description 1
102000004895 Lipoproteins Human genes 0.000 description 1
108090001030 Lipoproteins Proteins 0.000 description 1
241000186779 Listeria monocytogenes Species 0.000 description 1
206010024641 Listeriosis Diseases 0.000 description 1
206010024652 Liver abscess Diseases 0.000 description 1
101001038021 Lonomia obliqua Lopap Proteins 0.000 description 1
239000005089 Luciferase Substances 0.000 description 1
210000004322 M2 macrophage Anatomy 0.000 description 1
208000032271 Malignant tumor of penis Diseases 0.000 description 1
102000003939 Membrane transport proteins Human genes 0.000 description 1
108090000301 Membrane transport proteins Proteins 0.000 description 1
201000009906 Meningitis Diseases 0.000 description 1
206010027406 Mesothelioma Diseases 0.000 description 1
206010027480 Metastatic malignant melanoma Diseases 0.000 description 1
102000029749 Microtubule Human genes 0.000 description 1
108091022875 Microtubule Proteins 0.000 description 1
229930191564 Monensin Natural products 0.000 description 1
GAOZTHIDHYLHMS-UHFFFAOYSA-N Monensin A Natural products O1C(CC)(C2C(CC(O2)C2C(CC(C)C(O)(CO)O2)C)C)CCC1C(O1)(C)CCC21CC(O)C(C)C(C(C)C(OC)C(C)C(O)=O)O2 GAOZTHIDHYLHMS-UHFFFAOYSA-N 0.000 description 1
208000024599 Mooren ulcer Diseases 0.000 description 1
101100407308 Mus musculus Pdcd1lg2 gene Proteins 0.000 description 1
101000874159 Mus musculus Succinate dehydrogenase [ubiquinone] iron-sulfur subunit, mitochondrial Proteins 0.000 description 1
241000282341 Mustela putorius furo Species 0.000 description 1
101710135898 Myc proto-oncogene protein Proteins 0.000 description 1
102100038895 Myc proto-oncogene protein Human genes 0.000 description 1
241000187479 Mycobacterium tuberculosis Species 0.000 description 1
HRNLUBSXIHFDHP-UHFFFAOYSA-N N-(2-aminophenyl)-4-[[[4-(3-pyridinyl)-2-pyrimidinyl]amino]methyl]benzamide Chemical compound NC1=CC=CC=C1NC(=O)C(C=C1)=CC=C1CNC1=NC=CC(C=2C=NC=CC=2)=N1 HRNLUBSXIHFDHP-UHFFFAOYSA-N 0.000 description 1
206010028813 Nausea Diseases 0.000 description 1
206010028851 Necrosis Diseases 0.000 description 1
241000588650 Neisseria meningitidis Species 0.000 description 1
208000003788 Neoplasm Micrometastasis Diseases 0.000 description 1
206010029260 Neuroblastoma Diseases 0.000 description 1
239000000020 Nitrocellulose Substances 0.000 description 1
208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
102000017954 Nuclear factor of activated T cells (NFAT) Human genes 0.000 description 1
108050007058 Nuclear factor of activated T cells (NFAT) Proteins 0.000 description 1
208000022873 Ocular disease Diseases 0.000 description 1
102000043276 Oncogene Human genes 0.000 description 1
108700020796 Oncogene Proteins 0.000 description 1
241000712464 Orthomyxoviridae Species 0.000 description 1
208000010191 Osteitis Deformans Diseases 0.000 description 1
241000283903 Ovis aries Species 0.000 description 1
108090000854 Oxidoreductases Proteins 0.000 description 1
239000012271 PD-L1 inhibitor Substances 0.000 description 1
239000002033 PVDF binder Substances 0.000 description 1
208000027868 Paget disease Diseases 0.000 description 1
108090000526 Papain Proteins 0.000 description 1
229930040373 Paraformaldehyde Natural products 0.000 description 1
241000711504 Paramyxoviridae Species 0.000 description 1
206010033971 Paratyphoid fever Diseases 0.000 description 1
208000004788 Pars Planitis Diseases 0.000 description 1
208000037273 Pathologic Processes Diseases 0.000 description 1
241001494479 Pecora Species 0.000 description 1
206010034277 Pemphigoid Diseases 0.000 description 1
208000002471 Penile Neoplasms Diseases 0.000 description 1
206010034299 Penile cancer Diseases 0.000 description 1
108090000284 Pepsin A Proteins 0.000 description 1
239000001888 Peptone Substances 0.000 description 1
108010080698 Peptones Proteins 0.000 description 1
241000150350 Peribunyaviridae Species 0.000 description 1
208000005228 Pericardial Effusion Diseases 0.000 description 1
206010057249 Phagocytosis Diseases 0.000 description 1
108010009711 Phalloidine Proteins 0.000 description 1
241000223960 Plasmodium falciparum Species 0.000 description 1
241000242594 Platyhelminthes Species 0.000 description 1
206010035664 Pneumonia Diseases 0.000 description 1
229920001213 Polysorbate 20 Polymers 0.000 description 1
208000003971 Posterior uveitis Diseases 0.000 description 1
241000700625 Poxviridae Species 0.000 description 1
206010036790 Productive cough Diseases 0.000 description 1
108700030875 Programmed Cell Death 1 Ligand 2 Proteins 0.000 description 1
102100024213 Programmed cell death 1 ligand 2 Human genes 0.000 description 1
101800004937 Protein C Proteins 0.000 description 1
102000017975 Protein C Human genes 0.000 description 1
229940096437 Protein S Drugs 0.000 description 1
108010066124 Protein S Proteins 0.000 description 1
102000029301 Protein S Human genes 0.000 description 1
102100027378 Prothrombin Human genes 0.000 description 1
206010058877 Pseudomonal sepsis Diseases 0.000 description 1
201000004681 Psoriasis Diseases 0.000 description 1
201000002154 Pterygium Diseases 0.000 description 1
208000010378 Pulmonary Embolism Diseases 0.000 description 1
208000015634 Rectal Neoplasms Diseases 0.000 description 1
108091027981 Response element Proteins 0.000 description 1
208000007135 Retinal Neovascularization Diseases 0.000 description 1
206010038910 Retinitis Diseases 0.000 description 1
241000712907 Retroviridae Species 0.000 description 1
241000711931 Rhabdoviridae Species 0.000 description 1
239000012722 SDS sample buffer Substances 0.000 description 1
108091006629 SLC13A2 Proteins 0.000 description 1
241000607142 Salmonella Species 0.000 description 1
101800001700 Saposin-D Proteins 0.000 description 1
241000242678 Schistosoma Species 0.000 description 1
206010039705 Scleritis Diseases 0.000 description 1
206010039710 Scleroderma Diseases 0.000 description 1
206010040070 Septic Shock Diseases 0.000 description 1
238000012300 Sequence Analysis Methods 0.000 description 1
206010041101 Small intestinal obstruction Diseases 0.000 description 1
CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical class [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 1
208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 description 1
102100024470 Stabilin-2 Human genes 0.000 description 1
101710164033 Stabilin-2 Proteins 0.000 description 1
208000027073 Stargardt disease Diseases 0.000 description 1
208000007107 Stomach Ulcer Diseases 0.000 description 1
108010090804 Streptavidin Proteins 0.000 description 1
206010042434 Sudden death Diseases 0.000 description 1
241000282887 Suidae Species 0.000 description 1
208000033809 Suppuration Diseases 0.000 description 1
241000282898 Sus scrofa Species 0.000 description 1
201000009594 Systemic Scleroderma Diseases 0.000 description 1
206010042953 Systemic sclerosis Diseases 0.000 description 1
229940126547 T-cell immunoglobulin mucin-3 Drugs 0.000 description 1
229940123237 Taxane Drugs 0.000 description 1
BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 description 1
208000024313 Testicular Neoplasms Diseases 0.000 description 1
206010057644 Testis cancer Diseases 0.000 description 1
241000223997 Toxoplasma gondii Species 0.000 description 1
201000005485 Toxoplasmosis Diseases 0.000 description 1
108091023040 Transcription factor Proteins 0.000 description 1
102000040945 Transcription factor Human genes 0.000 description 1
101710150448 Transcriptional regulator Myc Proteins 0.000 description 1
102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
241000589884 Treponema pallidum Species 0.000 description 1
208000003721 Triple Negative Breast Neoplasms Diseases 0.000 description 1
229920004890 Triton X-100 Polymers 0.000 description 1
241000223109 Trypanosoma cruzi Species 0.000 description 1
102000001742 Tumor Suppressor Proteins Human genes 0.000 description 1
108010040002 Tumor Suppressor Proteins Proteins 0.000 description 1
102100040247 Tumor necrosis factor Human genes 0.000 description 1
208000037386 Typhoid Diseases 0.000 description 1
101150013568 US16 gene Proteins 0.000 description 1
201000006704 Ulcerative Colitis Diseases 0.000 description 1
206010064996 Ulcerative keratitis Diseases 0.000 description 1
206010046431 Urethral cancer Diseases 0.000 description 1
206010046458 Urethral neoplasms Diseases 0.000 description 1
102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
208000024248 Vascular System injury Diseases 0.000 description 1
208000012339 Vascular injury Diseases 0.000 description 1
206010047115 Vasculitis Diseases 0.000 description 1
238000011318 VeriStrat test Methods 0.000 description 1
108010003533 Viral Envelope Proteins Proteins 0.000 description 1
108010067390 Viral Proteins Proteins 0.000 description 1
206010047663 Vitritis Diseases 0.000 description 1
101100514842 Xenopus laevis mtus1 gene Proteins 0.000 description 1
230000002159 abnormal effect Effects 0.000 description 1
206010000269 abscess Diseases 0.000 description 1
NOSIYYJFMPDDSA-UHFFFAOYSA-N acepromazine Chemical compound C1=C(C(C)=O)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 NOSIYYJFMPDDSA-UHFFFAOYSA-N 0.000 description 1
229960005054 acepromazine Drugs 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
230000004913 activation Effects 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
208000009956 adenocarcinoma Diseases 0.000 description 1
239000000853 adhesive Substances 0.000 description 1
230000001070 adhesive effect Effects 0.000 description 1
238000001042 affinity chromatography Methods 0.000 description 1
230000004075 alteration Effects 0.000 description 1
231100000540 amenorrhea Toxicity 0.000 description 1
210000004381 amniotic fluid Anatomy 0.000 description 1
230000003321 amplification Effects 0.000 description 1
230000037005 anaesthesia Effects 0.000 description 1
206010002224 anaplastic astrocytoma Diseases 0.000 description 1
125000000129 anionic group Chemical group 0.000 description 1
201000004612 anterior uveitis Diseases 0.000 description 1
230000003263 anti-adenoviral effect Effects 0.000 description 1
230000003527 anti-angiogenesis Effects 0.000 description 1
230000001028 anti-proliverative effect Effects 0.000 description 1
238000009175 antibody therapy Methods 0.000 description 1
210000001742 aqueous humor Anatomy 0.000 description 1
239000012736 aqueous medium Substances 0.000 description 1
238000003491 array Methods 0.000 description 1
210000001367 artery Anatomy 0.000 description 1
206010003246 arthritis Diseases 0.000 description 1
210000003567 ascitic fluid Anatomy 0.000 description 1
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
230000003416 augmentation Effects 0.000 description 1
230000003190 augmentative effect Effects 0.000 description 1
230000001363 autoimmune Effects 0.000 description 1
230000000468 autoproteolytic effect Effects 0.000 description 1
229950002916 avelumab Drugs 0.000 description 1
210000003719 b-lymphocyte Anatomy 0.000 description 1
230000001580 bacterial effect Effects 0.000 description 1
208000022362 bacterial infectious disease Diseases 0.000 description 1
108010023562 beta 2-Glycoprotein I Proteins 0.000 description 1
229960000397 bevacizumab Drugs 0.000 description 1
210000000941 bile Anatomy 0.000 description 1
210000003445 biliary tract Anatomy 0.000 description 1
239000012148 binding buffer Substances 0.000 description 1
229960002685 biotin Drugs 0.000 description 1
235000020958 biotin Nutrition 0.000 description 1
239000011616 biotin Substances 0.000 description 1
230000000740 bleeding effect Effects 0.000 description 1
208000015294 blood coagulation disease Diseases 0.000 description 1
230000036765 blood level Effects 0.000 description 1
210000001124 body fluid Anatomy 0.000 description 1
239000010839 body fluid Substances 0.000 description 1
230000037396 body weight Effects 0.000 description 1
238000006664 bond formation reaction Methods 0.000 description 1
201000008275 breast carcinoma Diseases 0.000 description 1
210000004899 c-terminal region Anatomy 0.000 description 1
244000309466 calf Species 0.000 description 1
239000012830 cancer therapeutic Substances 0.000 description 1
229940041514 candida albicans extract Drugs 0.000 description 1
150000001768 cations Chemical class 0.000 description 1
239000006143 cell culture medium Substances 0.000 description 1
230000007910 cell fusion Effects 0.000 description 1
239000006285 cell suspension Substances 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
230000036755 cellular response Effects 0.000 description 1
210000003850 cellular structure Anatomy 0.000 description 1
230000002490 cerebral effect Effects 0.000 description 1
210000002939 cerumen Anatomy 0.000 description 1
210000003756 cervix mucus Anatomy 0.000 description 1
238000009104 chemotherapy regimen Methods 0.000 description 1
210000000038 chest Anatomy 0.000 description 1
208000028512 chlamydia infectious disease Diseases 0.000 description 1
229940038705 chlamydia trachomatis Drugs 0.000 description 1
210000003161 choroid Anatomy 0.000 description 1
230000006020 chronic inflammation Effects 0.000 description 1
208000037893 chronic inflammatory disorder Diseases 0.000 description 1
210000001268 chyle Anatomy 0.000 description 1
210000004913 chyme Anatomy 0.000 description 1
DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
229960004316 cisplatin Drugs 0.000 description 1
208000013056 classic Hodgkin lymphoma Diseases 0.000 description 1
230000010405 clearance mechanism Effects 0.000 description 1
230000035602 clotting Effects 0.000 description 1
238000011260 co-administration Methods 0.000 description 1
230000009852 coagulant defect Effects 0.000 description 1
230000015271 coagulation Effects 0.000 description 1
238000005345 coagulation Methods 0.000 description 1
229960004126 codeine Drugs 0.000 description 1
229960001338 colchicine Drugs 0.000 description 1
208000037966 cold tumor Diseases 0.000 description 1
210000001072 colon Anatomy 0.000 description 1
210000003022 colostrum Anatomy 0.000 description 1
235000021277 colostrum Nutrition 0.000 description 1
230000002301 combined effect Effects 0.000 description 1
150000004814 combretastatins Chemical class 0.000 description 1
238000012875 competitive assay Methods 0.000 description 1
230000009137 competitive binding Effects 0.000 description 1
230000002860 competitive effect Effects 0.000 description 1
230000001268 conjugating effect Effects 0.000 description 1
230000021615 conjugation Effects 0.000 description 1
210000000795 conjunctiva Anatomy 0.000 description 1
238000010276 construction Methods 0.000 description 1
239000000356 contaminant Substances 0.000 description 1
239000003433 contraceptive agent Substances 0.000 description 1
230000002254 contraceptive effect Effects 0.000 description 1
201000000159 corneal neovascularization Diseases 0.000 description 1
208000026758 coronary atherosclerosis Diseases 0.000 description 1
208000002528 coronary thrombosis Diseases 0.000 description 1
230000002596 correlated effect Effects 0.000 description 1
210000004748 cultured cell Anatomy 0.000 description 1
238000005520 cutting process Methods 0.000 description 1
210000002726 cyst fluid Anatomy 0.000 description 1
210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
230000002950 deficient Effects 0.000 description 1
230000000779 depleting effect Effects 0.000 description 1
238000000502 dialysis Methods 0.000 description 1
230000004069 differentiation Effects 0.000 description 1
229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
230000009429 distress Effects 0.000 description 1
231100000673 dose–response relationship Toxicity 0.000 description 1
230000007783 downstream signaling Effects 0.000 description 1
239000003651 drinking water Substances 0.000 description 1
235000020188 drinking water Nutrition 0.000 description 1
239000000975 dye Substances 0.000 description 1
230000002526 effect on cardiovascular system Effects 0.000 description 1
238000004520 electroporation Methods 0.000 description 1
230000008030 elimination Effects 0.000 description 1
238000003379 elimination reaction Methods 0.000 description 1
238000010828 elution Methods 0.000 description 1
239000012149 elution buffer Substances 0.000 description 1
230000002357 endometrial effect Effects 0.000 description 1
210000003989 endothelium vascular Anatomy 0.000 description 1
230000007613 environmental effect Effects 0.000 description 1
102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 1
108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 1
229960001433 erlotinib Drugs 0.000 description 1
AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 1
230000001747 exhibiting effect Effects 0.000 description 1
210000003722 extracellular fluid Anatomy 0.000 description 1
208000011323 eye infectious disease Diseases 0.000 description 1
206010016165 failure to thrive Diseases 0.000 description 1
230000012953 feeding on blood of other organism Effects 0.000 description 1
230000004720 fertilization Effects 0.000 description 1
210000004700 fetal blood Anatomy 0.000 description 1
230000001605 fetal effect Effects 0.000 description 1
239000000835 fiber Substances 0.000 description 1
230000001497 fibrovascular Effects 0.000 description 1
238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
210000001733 follicular fluid Anatomy 0.000 description 1
230000008014 freezing Effects 0.000 description 1
238000007710 freezing Methods 0.000 description 1
230000002538 fungal effect Effects 0.000 description 1
230000002068 genetic effect Effects 0.000 description 1
PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
239000010931 gold Substances 0.000 description 1
229910052737 gold Inorganic materials 0.000 description 1
230000012010 growth Effects 0.000 description 1
238000003306 harvesting Methods 0.000 description 1
231100001261 hazardous Toxicity 0.000 description 1
201000000459 head and neck squamous cell carcinoma Diseases 0.000 description 1
230000036541 health Effects 0.000 description 1
230000003862 health status Effects 0.000 description 1
229940037467 helicobacter pylori Drugs 0.000 description 1
229960002897 heparin Drugs 0.000 description 1
229920000669 heparin Polymers 0.000 description 1
208000010710 hepatitis C virus infection Diseases 0.000 description 1
230000036732 histological change Effects 0.000 description 1
239000005556 hormone Substances 0.000 description 1
229940088597 hormone Drugs 0.000 description 1
210000004251 human milk Anatomy 0.000 description 1
235000020256 human milk Nutrition 0.000 description 1
208000013653 hyalitis Diseases 0.000 description 1
OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 description 1
230000007062 hydrolysis Effects 0.000 description 1
238000006460 hydrolysis reaction Methods 0.000 description 1
230000001969 hypertrophic effect Effects 0.000 description 1
230000007954 hypoxia Effects 0.000 description 1
229940121569 ieramilimab Drugs 0.000 description 1
230000005965 immune activity Effects 0.000 description 1
230000005746 immune checkpoint blockade Effects 0.000 description 1
210000004201 immune sera Anatomy 0.000 description 1
229940042743 immune sera Drugs 0.000 description 1
230000006058 immune tolerance Effects 0.000 description 1
230000036039 immunity Effects 0.000 description 1
238000000760 immunoelectrophoresis Methods 0.000 description 1
238000003125 immunofluorescent labeling Methods 0.000 description 1
230000002163 immunogen Effects 0.000 description 1
238000001114 immunoprecipitation Methods 0.000 description 1
210000005008 immunosuppressive cell Anatomy 0.000 description 1
230000003116 impacting effect Effects 0.000 description 1
208000000509 infertility Diseases 0.000 description 1
230000036512 infertility Effects 0.000 description 1
208000021267 infertility disease Diseases 0.000 description 1
238000011221 initial treatment Methods 0.000 description 1
230000015788 innate immune response Effects 0.000 description 1
230000035992 intercellular communication Effects 0.000 description 1
230000008611 intercellular interaction Effects 0.000 description 1
229960003130 interferon gamma Drugs 0.000 description 1
238000012361 intermediate testing Methods 0.000 description 1
230000029225 intracellular protein transport Effects 0.000 description 1
230000002601 intratumoral effect Effects 0.000 description 1
238000010253 intravenous injection Methods 0.000 description 1
238000011835 investigation Methods 0.000 description 1
238000002955 isolation Methods 0.000 description 1
238000005304 joining Methods 0.000 description 1
210000001117 keloid Anatomy 0.000 description 1
201000010666 keratoconjunctivitis Diseases 0.000 description 1
230000035984 keratolysis Effects 0.000 description 1
229960003299 ketamine Drugs 0.000 description 1
231100001263 laboratory chemical safety summary Toxicity 0.000 description 1
210000000867 larynx Anatomy 0.000 description 1
239000004816 latex Substances 0.000 description 1
229920000126 latex Polymers 0.000 description 1
210000005240 left ventricle Anatomy 0.000 description 1
229940115932 legionella pneumophila Drugs 0.000 description 1
230000003902 lesion Effects 0.000 description 1
210000000265 leukocyte Anatomy 0.000 description 1
201000002364 leukopenia Diseases 0.000 description 1
231100001022 leukopenia Toxicity 0.000 description 1
230000002197 limbic effect Effects 0.000 description 1
238000011528 liquid biopsy Methods 0.000 description 1
238000011068 loading method Methods 0.000 description 1
230000004807 localization Effects 0.000 description 1
230000005923 long-lasting effect Effects 0.000 description 1
206010025135 lupus erythematosus Diseases 0.000 description 1
210000002751 lymph Anatomy 0.000 description 1
239000006166 lysate Substances 0.000 description 1
238000012423 maintenance Methods 0.000 description 1
201000004792 malaria Diseases 0.000 description 1
208000026037 malignant tumor of neck Diseases 0.000 description 1
210000004962 mammalian cell Anatomy 0.000 description 1
208000027202 mammary Paget disease Diseases 0.000 description 1
235000013372 meat Nutrition 0.000 description 1
230000010534 mechanism of action Effects 0.000 description 1
210000004779 membrane envelope Anatomy 0.000 description 1
230000005055 memory storage Effects 0.000 description 1
206010027191 meningioma Diseases 0.000 description 1
210000004914 menses Anatomy 0.000 description 1
230000003821 menstrual periods Effects 0.000 description 1
230000009401 metastasis Effects 0.000 description 1
208000021039 metastatic melanoma Diseases 0.000 description 1
210000004688 microtubule Anatomy 0.000 description 1
230000010060 microvascular dysfunction Effects 0.000 description 1
235000013336 milk Nutrition 0.000 description 1
210000004080 milk Anatomy 0.000 description 1
239000008267 milk Substances 0.000 description 1
230000011278 mitosis Effects 0.000 description 1
238000002156 mixing Methods 0.000 description 1
239000002991 molded plastic Substances 0.000 description 1
229960005358 monensin Drugs 0.000 description 1
GAOZTHIDHYLHMS-KEOBGNEYSA-N monensin A Chemical compound C([C@@](O1)(C)[C@H]2CC[C@@](O2)(CC)[C@H]2[C@H](C[C@@H](O2)[C@@H]2[C@H](C[C@@H](C)[C@](O)(CO)O2)C)C)C[C@@]21C[C@H](O)[C@@H](C)[C@@H]([C@@H](C)[C@@H](OC)[C@H](C)C(O)=O)O2 GAOZTHIDHYLHMS-KEOBGNEYSA-N 0.000 description 1
238000012544 monitoring process Methods 0.000 description 1
210000003097 mucus Anatomy 0.000 description 1
230000000869 mutational effect Effects 0.000 description 1
210000000066 myeloid cell Anatomy 0.000 description 1
YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 1
230000008693 nausea Effects 0.000 description 1
210000003739 neck Anatomy 0.000 description 1
230000017074 necrotic cell death Effects 0.000 description 1
230000001613 neoplastic effect Effects 0.000 description 1
201000003142 neovascular glaucoma Diseases 0.000 description 1
210000000440 neutrophil Anatomy 0.000 description 1
229920001220 nitrocellulos Polymers 0.000 description 1
231100000956 nontoxicity Toxicity 0.000 description 1
238000003199 nucleic acid amplification method Methods 0.000 description 1
239000002773 nucleotide Substances 0.000 description 1
125000003729 nucleotide group Chemical group 0.000 description 1
235000015097 nutrients Nutrition 0.000 description 1
238000005457 optimization Methods 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
201000008482 osteoarthritis Diseases 0.000 description 1
210000001672 ovary Anatomy 0.000 description 1
230000036542 oxidative stress Effects 0.000 description 1
108010071584 oxidized low density lipoprotein Proteins 0.000 description 1
239000001301 oxygen Substances 0.000 description 1
229910052760 oxygen Inorganic materials 0.000 description 1
229940108931 paclitaxel 100 mg Drugs 0.000 description 1
230000000242 pagocytic effect Effects 0.000 description 1
210000001819 pancreatic juice Anatomy 0.000 description 1
229960005489 paracetamol Drugs 0.000 description 1
229920002866 paraformaldehyde Polymers 0.000 description 1
244000045947 parasite Species 0.000 description 1
230000008506 pathogenesis Effects 0.000 description 1
230000009054 pathological process Effects 0.000 description 1
239000013610 patient sample Substances 0.000 description 1
229940121656 pd-l1 inhibitor Drugs 0.000 description 1
239000008188 pellet Substances 0.000 description 1
QOFFJEBXNKRSPX-ZDUSSCGKSA-N pemetrexed Chemical compound C1=N[C]2NC(N)=NC(=O)C2=C1CCC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 QOFFJEBXNKRSPX-ZDUSSCGKSA-N 0.000 description 1
229960005079 pemetrexed Drugs 0.000 description 1
239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
235000019319 peptone Nutrition 0.000 description 1
210000004912 pericardial fluid Anatomy 0.000 description 1
230000000737 periodic effect Effects 0.000 description 1
238000002823 phage display Methods 0.000 description 1
210000001539 phagocyte Anatomy 0.000 description 1
230000008782 phagocytosis Effects 0.000 description 1
JTJMJGYZQZDUJJ-UHFFFAOYSA-N phencyclidine Chemical compound C1CCCCN1C1(C=2C=CC=CC=2)CCCCC1 JTJMJGYZQZDUJJ-UHFFFAOYSA-N 0.000 description 1
239000013600 plasmid vector Substances 0.000 description 1
210000004910 pleural fluid Anatomy 0.000 description 1
208000025223 poliovirus infection Diseases 0.000 description 1
238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
229920002981 polyvinylidene fluoride Polymers 0.000 description 1
238000010837 poor prognosis Methods 0.000 description 1
230000016412 positive regulation of cytokine production Effects 0.000 description 1
230000002980 postoperative effect Effects 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
239000002244 precipitate Substances 0.000 description 1
238000001556 precipitation Methods 0.000 description 1
230000002265 prevention Effects 0.000 description 1
239000000092 prognostic biomarker Substances 0.000 description 1
230000000644 propagated effect Effects 0.000 description 1
XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 1
210000004908 prostatic fluid Anatomy 0.000 description 1
229960000856 protein c Drugs 0.000 description 1
230000017854 proteolysis Effects 0.000 description 1
238000000575 proteomic method Methods 0.000 description 1
238000011317 proteomic test Methods 0.000 description 1
229940039716 prothrombin Drugs 0.000 description 1
239000012264 purified product Substances 0.000 description 1
210000004915 pus Anatomy 0.000 description 1
239000002510 pyrogen Substances 0.000 description 1
238000004445 quantitative analysis Methods 0.000 description 1
238000010791 quenching Methods 0.000 description 1
230000000171 quenching effect Effects 0.000 description 1
229950011613 racotumomab Drugs 0.000 description 1
238000011127 radiochemotherapy Methods 0.000 description 1
238000003259 recombinant expression Methods 0.000 description 1
206010038038 rectal cancer Diseases 0.000 description 1
201000001275 rectum cancer Diseases 0.000 description 1
230000011514 reflex Effects 0.000 description 1
238000007634 remodeling Methods 0.000 description 1
230000008439 repair process Effects 0.000 description 1
230000001850 reproductive effect Effects 0.000 description 1
210000004994 reproductive system Anatomy 0.000 description 1
230000000284 resting effect Effects 0.000 description 1
210000001525 retina Anatomy 0.000 description 1
230000002207 retinal effect Effects 0.000 description 1
206010039073 rheumatoid arthritis Diseases 0.000 description 1
210000005241 right ventricle Anatomy 0.000 description 1
231100000279 safety data Toxicity 0.000 description 1
210000003296 saliva Anatomy 0.000 description 1
231100000241 scar Toxicity 0.000 description 1
230000037387 scars Effects 0.000 description 1
201000004409 schistosomiasis Diseases 0.000 description 1
210000002374 sebum Anatomy 0.000 description 1
230000036303 septic shock Effects 0.000 description 1
231100000161 signs of toxicity Toxicity 0.000 description 1
239000010703 silicon Substances 0.000 description 1
229910052710 silicon Inorganic materials 0.000 description 1
239000000377 silicon dioxide Substances 0.000 description 1
238000011125 single therapy Methods 0.000 description 1
238000009097 single-agent therapy Methods 0.000 description 1
208000017520 skin disease Diseases 0.000 description 1
235000017557 sodium bicarbonate Nutrition 0.000 description 1
229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 1
239000000223 sodium ionophore Substances 0.000 description 1
229950007213 spartalizumab Drugs 0.000 description 1
230000009870 specific binding Effects 0.000 description 1
210000000952 spleen Anatomy 0.000 description 1
210000004988 splenocyte Anatomy 0.000 description 1
208000000995 spontaneous abortion Diseases 0.000 description 1
210000003802 sputum Anatomy 0.000 description 1
208000024794 sputum Diseases 0.000 description 1
238000010186 staining Methods 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
239000007858 starting material Substances 0.000 description 1
239000008223 sterile water Substances 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
238000003756 stirring Methods 0.000 description 1
210000002784 stomach Anatomy 0.000 description 1
238000013517 stratification Methods 0.000 description 1
239000000126 substance Substances 0.000 description 1
238000006467 substitution reaction Methods 0.000 description 1
229960001796 sunitinib Drugs 0.000 description 1
WINHZLLDWRZWRT-ATVHPVEESA-N sunitinib Chemical compound CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C WINHZLLDWRZWRT-ATVHPVEESA-N 0.000 description 1
230000001502 supplementing effect Effects 0.000 description 1
238000011477 surgical intervention Methods 0.000 description 1
230000002459 sustained effect Effects 0.000 description 1
210000004243 sweat Anatomy 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
208000011580 syndromic disease Diseases 0.000 description 1
210000001179 synovial fluid Anatomy 0.000 description 1
201000004595 synovitis Diseases 0.000 description 1
208000006379 syphilis Diseases 0.000 description 1
230000001839 systemic circulation Effects 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
201000000596 systemic lupus erythematosus Diseases 0.000 description 1
229960001603 tamoxifen Drugs 0.000 description 1
229940126625 tavolimab Drugs 0.000 description 1
DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 description 1
210000001138 tear Anatomy 0.000 description 1
229940066453 tecentriq Drugs 0.000 description 1
229960004964 temozolomide Drugs 0.000 description 1
201000003120 testicular cancer Diseases 0.000 description 1
ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
238000011287 therapeutic dose Methods 0.000 description 1
230000004797 therapeutic response Effects 0.000 description 1
206010043554 thrombocytopenia Diseases 0.000 description 1
210000001685 thyroid gland Anatomy 0.000 description 1
238000004448 titration Methods 0.000 description 1
231100000041 toxicology testing Toxicity 0.000 description 1
230000005030 transcription termination Effects 0.000 description 1
238000001890 transfection Methods 0.000 description 1
230000009466 transformation Effects 0.000 description 1
230000032258 transport Effects 0.000 description 1
229960000575 trastuzumab Drugs 0.000 description 1
230000001960 triggered effect Effects 0.000 description 1
238000011295 triple combination therapy Methods 0.000 description 1
208000022679 triple-negative breast carcinoma Diseases 0.000 description 1
201000002311 trypanosomiasis Diseases 0.000 description 1
230000005909 tumor killing Effects 0.000 description 1
201000008297 typhoid fever Diseases 0.000 description 1
231100000402 unacceptable toxicity Toxicity 0.000 description 1
230000003827 upregulation Effects 0.000 description 1
229950005972 urelumab Drugs 0.000 description 1
210000003932 urinary bladder Anatomy 0.000 description 1
230000002485 urinary effect Effects 0.000 description 1
210000002229 urogenital system Anatomy 0.000 description 1
229950003520 utomilumab Drugs 0.000 description 1
229960005486 vaccine Drugs 0.000 description 1
230000025033 vasoconstriction Effects 0.000 description 1
229920002554 vinyl polymer Polymers 0.000 description 1
230000017613 viral reproduction Effects 0.000 description 1
230000029302 virus maturation Effects 0.000 description 1
230000004393 visual impairment Effects 0.000 description 1
238000012800 visualization Methods 0.000 description 1
210000004916 vomit Anatomy 0.000 description 1
230000008673 vomiting Effects 0.000 description 1
BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 1
229960001600 xylazine Drugs 0.000 description 1
239000012138 yeast extract Substances 0.000 description 1
229940055760 yervoy Drugs 0.000 description 1